Ativo Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ativo Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,604	Closed	-$1.97M	–	122
2021 Q4	$1.97M	Hold	2,604	–	–	0.87%	24
2021 Q3	$1.94M	Hold	2,604	–	–	0.91%	18
2021 Q2	$1.68M	Hold	2,604	–	–	0.71%	42
2021 Q1	$1.49M	Hold	2,604	–	–	0.63%	56
2020 Q4	$1.52M	Sell	2,604 -3	-0.1%	-$1.71K	0.65%	45
2020 Q3	$1.34M	Sell	2,607 -356	-12%	-$180K	0.65%	48
2020 Q2	$1.34M	Hold	2,963	–	–	0.72%	43
2020 Q1	$1.04M	Buy	+2,963	New	+$1.09M	0.65%	50

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ativo Capital Management's BIO Position: Q1 2022 in Review

Ativo Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 2,604 shares — an estimated $1.97M sold.

Ativo Capital Management first reported a position in BIO in Q1 2020 and held it in 8 quarters. The position peaked at $1.97M in Q4 2021. 516 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Ativo Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Ativo Capital Management sold 2,604 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $1.97M.
Ativo Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 8 quarters.
Ativo Capital Management's Bio-Rad Laboratories Class A position peaked at $1.97M in Q4 2021.
516 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Ativo Capital Management's 13F filing for Q1 2022, filed 13 May 2022.